Login / Signup

Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge.

Dae Hyun LeeMerna ArmaniousJessica HuangDaniel JeongMihaela DrutaMichael G Fradley
Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
To the best of our knowledge, this is the first reported case of successful re-challenge of pembrolizumab after an episode of myocarditis. In patients with mild myocarditis and no evidence of left ventricular dysfunction, re-challenge may be a viable option. However, close monitoring for the development of heart failure, cardiomyopathy, or serious arrhythmias is necessary to ensure patient safety.
Keyphrases